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| NEUROFIBROMATOSIS TYPE IS A MULTI-ORGAN SYNDROME OFTEN DIAGNOSED BY DERMATOLOGISTS
Neurofibromatosis type 1, NF1 (MIM #162200), formerly known as von Recklinghausen's disease, is a common monogenic genodermatosis with an incidence of 1:2000, as recently shown in Finland. [1] NF1 is caused by mutations in a Ras pathway gene and is thus by definition a RASopathy. It is characterized by neural, cutaneous and skeletal abnormalities, but has a highly variable phenotype and causes complications in several organ systems. The hallmarks of NF1 are visible on the skin: cutaneous neurofibromas, café au lait pigment spots and freckles of skinfolds (s1). Larger tumors, so-called plexiform neurofibromas, are present in more than half of the patients (s2). The central nervous system may also be affected: symptoms of attention deficit-hyperactivity disorder, mild cognitive impairment, delay in motoric development, reduced social function including features of autism spectrum disorders and various problems in speech are common (s3). [2] More than half of the patients have learning disabilities (s4). Among the skeletal defects associated with NF1 are osteoporosis, pseudarthrosis of the long bones and dystrophic scoliosis. [3] NF1 is the most common monogenic syndrome known to predispose to cancer, and the patients carry a high risk of malignancies [4, 5] (s5) and early death.
[1]
| NF1 ENCODES THE TUMOR SUPPRESSOR PROTEIN NEUROFIBROMIN
The NF1 gene is located on chromosome 17, band q11.2. [6] The gene is complex and large: it spans over more than 280 kb of genomic DNA, contains 57 constitutive exons and has at least three alternatively spliced exons (s6) (Figure 1 ). [6] The gene encodes neurofibromin, a 320-kDa, 2818-aa protein (s7, s8) ( Figure 1 ). Neurofibromin is ubiquitously expressed, but its protein levels vary in different tissues by the developmental and differentiation stages of the organism (s9, s10). Neurofibromin regulates cell survival, proliferation and differentiation through proteins such as Ras and adenylate cyclase ( Figure 2 ).
Neurofibromin is a GTPase-activating protein (GAP) and functions as a negative regulator of the Ras pathway activity (s11, s12). The GAPrelated domain (GRD) of neurofibromin has been extensively characterized and represents only about 10% of the neurofibromin protein sequence. However, the structure and function of neurofibromin are still not very well known and data on the subject are partly based on single reports. Several interactions of neurofibromin are shown in 
| NORMAL KERATINOCYTES AND NF1 EXPRESSION
Neurofibromin is expressed in developing human and rodent epidermis (s14-s17) and in cultured keratinocytes (s18-s23 
| NF1 GENE AND TUMORIGENESIS
Although constitutional mutations of the NF1 gene are related to a high risk for malignancies, the cutaneous neurofibromas invariably retain their benign phenotype. Cutaneous neurofibromas are composed of multiple cell types, including Schwann cells, fibroblasts, perineurial cells and mast cells. [7] The tumors contain a subpopulation of Schwann cells which harbour a second hit in the NF1 gene (s24). Each cutaneous neurofibroma has its own unique second hit mutation, and only one second hit mutation is found in each tumor, indicating that the Schwann cell population is clonal. Cutaneous neurofibromas are traditionally believed to arise from small nerve tributaries of the skin, but it has also been suggested that these tumors develop from the recruitment of multipotent precursor cells with two hits in the NF1 gene and that these precursor cells have originally resided in association with hair follicles. [8] This is in line with a study using a bioengineered mouse model which showed that the implantation of skin-derived precursor cells with two mutated Nf1 alleles into mice heterozygous for Nf1 results in neurofibromas (s25). of MPNSTs compared to the general population and the lifetime risk is about 15%.
[5] In addition to well-defined pigmentary defects, a slight overall hyperpigmentation of the skin is common in NF1 patients. This is explained by a reduced number of keratinocytes per melanocytes, which, furthermore, has been proposed as evidence of a more general impairment of the organization of tissues (s32). Cultured melanocytes carrying an NF1 mutation are also morphologically disorganized; they form more than two dendrites per cell, while normal melanocytes have two dendrites arranged at a 180° angle to each other (s33).
| NEUROFIBROMIN REGULATES MELANOGENESIS IN MELANOCYTES
Melanocytes cultured from normal-appearing skin of NF1 patients contain more melanin than normal melanocytes, but the highest melanin content occurs in melanocytes cultured from café au lait spots (s34). In analogy to the Schwann cells in cutaneous neurofibromas, melanocytes of café au lait spots carry a second hit or somatic mutation of the NF1 gene (s35), which leads to inactivation of both NF1 alleles. It is noteworthy that, like cutaneous neurofibromas, café au lait spots do not have a propensity for malignant transformation. [5] A recent work showed that melanin synthesis increases if the NF1 gene is inactivated (s36). The molecular mechanisms are linked to an increased activity of cAMP-mediated PKA and Erk signalling pathways, which, in turn, leads to overexpression of the key transcription factor MITF and melanogenic enzymes, such as tyrosinase and TRP-2/ dopachrome tautomerase. These findings suggest that the NF1 gene specifically regulates melanogenesis.
| NF1 MUTATIONS DRIVE MELANOMAGENESIS
A strongly increased cancer risk is associated with the NF1 syndrome, but somatic mutations of the NF1 gene are common in several cancers of patients with no NF1. These tumors include mammary, pulmonary, and ovarian cancers, the glioblastoma and skin cancers (s37-s39). The prevalence of NF1 mutations is 13-15% in melanomas (s40-s43) and 6.6% in advanced-stage cutaneous squamous cell carcinoma (s44).
NF1 was recently found to be the third commonly mutated gene in melanoma (s43). Selective pressure induced by therapy may change the mutational spectrum of melanomas, but NF1 is also commonly mutated in tumors that have not been treated (s43).
The most common mutations in NRAS or BRAF genes in melanomas lead to hyperactivity of the mitogen-activated protein kinase ( No mutational hot spots have been identified in NF1, which explains why approaches set out to find recurrent mutations may not identify the role of NF1 in cancer (Figure 1 ). In addition, the size and complexity of the NF1 gene have also hampered its sequencing up until the most recent studies (s48). [9] Loss of NF1 expression may be caused not only by mutations but also by epigenetic mechanisms like miRNA-mediated regulation (s49).
NF1 mutations have typically been identified in melanomas with
extensive UV-induced damage (s41-s43, s45, s51). Patients with NF1-mutant melanomas were also of more advanced age than patients with NF1 intact. There is an interesting analogy between melanoma and lung cancer: NF1 mutations are present especially in lung adenocarcinomas with smoking-associated damage (s52). Either high mutagenicity is required to induce NF1 mutations or NF1 may be especially prone to damage caused by external mutagens.
| OPEN QUESTIONS AND FUTURE RESEARCH
Neurofibromin is best known as a RasGAP, although this function is only attributed to a small part of the large protein. Schwann cells of cutaneous neurofibromas and melanocytes of café au lait spots harbour mutations in both alleles of the NF1 gene.
It is a fascinating observation that these most typical characteristics of NF1 do not undergo malignant transformation despite the mutations, while mutations in NF1 and other genes of the Ras pathway drive cancers in other instances. In an effort to identify new targets for treating melanoma, studying the role of the NF1 gene, together with other genes of the Ras-MAPK pathway, could be most rewarding.
Further studies on the regulation of NF1 in various other cancer types are needed, as well, to identify the role of NF1 for tumorigenesis and malignancy.
| CONCLUSIONS AND PERSPECTIVES
Mutations of the NF1 gene are not only the cause of neurofibromatosis syndrome, but are also found in cancers of the general population. The accumulating sequence data from various cancers will further elucidate the role of NF1 for malignant transformation and cancer progression in humans. Simultaneously, reversing the effects of NF1 mutations will become an attractive target for cancer treatment and for managing the tumor load of patients with neurofibromatosis.
